H Woehrle1, O Oldenburg2,3, S Stadler4, M Arzt5. 1. Schlaf- und Beatmungszentrum Blaubeuren, Lungenzentrum Ulm, Ulm, Deutschland. 2. Klinik für Kardiologie, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Deutschland. 3. Ludgerus-Kliniken, Clemenshospital, Lehrkrankenhaus der Westfälischen Wilhelms-Universität, Münster, Deutschland. 4. Schlafmedizinisches Zentrum, Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland. 5. Schlafmedizinisches Zentrum, Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland. michael.arzt@klinik.uni-regensburg.de.
Abstract
BACKGROUND: Since sleep apnea often occurs in heart failure, physicians regularly need to decide whether further diagnostic procedures and/or treatment are required. OBJECTIVES: Which types of sleep apnea occur in heart failure patients? When is treatment needed? Which treatments and treatment goals are appropriate? MATERIALS AND METHODS: Clinical trials and guidelines as well as their implementation in clinical practice are discussed. RESULTS: At least 40% of patients with heart failure, both with reduced and preserved left ventricular ejection fraction (HFrEF and HFpEF, respectively), suffer from relevant sleep apnea. In heart failure patients both obstructive and central sleep apnea are associated with increased mortality. In HFrEF as well as in HFpEF patients with obstructive sleep apnea, treatment with continuous positive airway pressure (CPAP) achieves symptomatic and functional improvements. In patients with HFpEF, positive airway pressure treatment of central sleep apnea may be beneficial. In patients with HFrEF and left ventricular ejection fraction ≤45%, adaptive servoventilation is contraindicated. CONCLUSIONS: Sleep apnea is highly prevalent in heart failure patients and its treatment in specific patient groups can improve symptoms and functional outcomes. Thus, testing for sleep apnea is recommended.
BACKGROUND: Since sleep apnea often occurs in heart failure, physicians regularly need to decide whether further diagnostic procedures and/or treatment are required. OBJECTIVES: Which types of sleep apnea occur in heart failurepatients? When is treatment needed? Which treatments and treatment goals are appropriate? MATERIALS AND METHODS: Clinical trials and guidelines as well as their implementation in clinical practice are discussed. RESULTS: At least 40% of patients with heart failure, both with reduced and preserved left ventricular ejection fraction (HFrEF and HFpEF, respectively), suffer from relevant sleep apnea. In heart failurepatients both obstructive and central sleep apnea are associated with increased mortality. In HFrEF as well as in HFpEF patients with obstructive sleep apnea, treatment with continuous positive airway pressure (CPAP) achieves symptomatic and functional improvements. In patients with HFpEF, positive airway pressure treatment of central sleep apnea may be beneficial. In patients with HFrEF and left ventricular ejection fraction ≤45%, adaptive servoventilation is contraindicated. CONCLUSIONS:Sleep apnea is highly prevalent in heart failurepatients and its treatment in specific patient groups can improve symptoms and functional outcomes. Thus, testing for sleep apnea is recommended.
Authors: Hanqiao Wang; John D Parker; Gary E Newton; John S Floras; Susanna Mak; Kuo-Liang Chiu; Pimon Ruttanaumpawan; George Tomlinson; T Douglas Bradley Journal: J Am Coll Cardiol Date: 2007-04-02 Impact factor: 24.094
Authors: Owen D Lyons; John S Floras; Alexander G Logan; Robert Beanlands; Joaquin Durán Cantolla; Michael Fitzpatrick; John Fleetham; R John Kimoff; Richard S T Leung; Geraldo Lorenzi Filho; Pierre Mayer; Lisa Mielniczuk; Debra L Morrison; Clodagh M Ryan; Frederic Series; George A Tomlinson; Anna Woo; Michael Arzt; Sairam Parthasarathy; Stefania Redolfi; Takatoshi Kasai; Gianfranco Parati; Diego H Delgado; T Douglas Bradley Journal: Eur J Heart Fail Date: 2017-04 Impact factor: 15.534
Authors: Dennis Hwang; Jeremiah W Chang; Adam V Benjafield; Maureen E Crocker; Colleen Kelly; Kendra A Becker; Joseph B Kim; Rosa R Woodrum; Joanne Liang; Stephen F Derose Journal: Am J Respir Crit Care Med Date: 2018-01-01 Impact factor: 21.405
Authors: Patrick Lévy; Malcolm Kohler; Walter T McNicholas; Ferran Barbé; R Doug McEvoy; Virend K Somers; Lena Lavie; Jean-Louis Pépin Journal: Nat Rev Dis Primers Date: 2015-06-25 Impact factor: 52.329
Authors: Andrea Hetzenecker; Pierre Escourrou; Samuel T Kuna; Frederic Series; Keir Lewis; Christoph Birner; Michael Pfeifer; Michael Arzt Journal: Sleep Med Date: 2015-10-20 Impact factor: 3.492
Authors: Michael Arzt; Olaf Oldenburg; Andrea Graml; Erland Erdmann; Helmut Teschler; Karl Wegscheider; Anna Suling; Holger Woehrle Journal: J Am Heart Assoc Date: 2017-11-29 Impact factor: 5.501